ALEC Insider Trading
Insider Ownership Percentage: 9.10%
Insider Buying (Last 12 Months): $0.00
Insider Selling (Last 12 Months): $718,275.08
Alector Share Price & Price History
Current Price: $0.95
Price Change: ▲ Price Increase of +0.0457 (5.05%)
As of 04/11/2025 05:00 PM ET
Alector Insider Trading History
Alector Institutional Trading History
Data available starting January 2016
Alector, Inc., a clinical stage biopharmaceutical company, develops therapies for the treatment of neurodegeneration diseases. Its products include AL001, an immune activity in the brain with genetic links to multiple neurodegenerative disorders, which is in Phase III clinical trial for the treatment of frontotemporal dementia, Alzheimer's, Parkinson's, and amyotrophic lateral sclerosis diseases; and AL101 that is in Phase I clinical trial for the treatment of neurodegenerative diseases, including Alzheimer's and Parkinson's diseases. The company also offers AL002, a product candidate that is in Phase II clinical trial for the treatment of Alzheimer's disease. Alector, Inc. has a collaboration agreement with Adimab, LLC for the research and development of antibodies; and a strategic collaboration agreement with GlaxoSmithKline plc for the development and commercialization of monoclonal antibodies, such as AL001 and AL101 to treat neurodegenerative diseases. The company was founded in 2013 and is headquartered in South San Francisco, California.
Read More on Alector
Volume
565,681 shs
Average Volume
773,286 shs
Market Capitalization
$94.13 million
P/E Ratio
N/A
Dividend Yield
N/A
Beta
0.73
Who are the company insiders with the largest holdings of Alector?
Alector's top insider investors include:
- Polaris Venture Management Co (Major Shareholder)
- Arnon Rosenthal (CEO)
- Sara Kenkare-Mitra (Insider)
- Marc Grasso (CFO)
- Gary Romano (Insider)
- Paula Hammond (Director)
Learn More about top insider investors at Alector.